What type of drug is selinexor?
Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by killing cancer cells.
What is selinexor used for?
Generic Name: selinexor This medication is used to treat cancer. Selinexor works by slowing or stopping the growth of cancer cells.
Is selinexor a chemotherapy drug?
Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
What company makes selinexor?
Selinexor was developed by Karyopharm Therapeutics, a pharmaceutical company focused on the development of drugs that target nuclear transport. It was approved in the United States in July 2019, on the basis of a single-arm Phase IIb clinical trial.
Is Selinexor FDA approved?
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
How long does it take for Selinexor to work?
Selinexor was approved on the basis of safety and efficacy data from 83 patients with RRMM who were treated with the drug in combination with dexamethasone. The overall response rate was 25%. The median time to first response was 4 weeks (range, 1 to 10 weeks). The median duration of response was 3.8 months.
What is the most common side effect associated with Selinexor?
Nausea, vomiting, diarrhea, loss of appetite, or weight loss may occur with selinexor, which can be severe and cause dehydration. Your doctor may give you medicine or other treatments for these. Check with your doctor right away if you notice that you are losing weight or have a decrease in appetite.
Can Myeloma be cured completely?
While there is no cure for multiple myeloma, the cancer can be managed successfully in many patients for years. The common types of treatments used for multiple myeloma are described below. Your care plan may also include treatment for symptoms and side effects, an important part of cancer care.
What are the side effects of Xpovio?
XPOVIO can cause serious side effects, including:
- Low platelet counts.
- Low white blood cell counts.
- Serious infections.
- Neurologic side effects.
- Nausea, vomiting and/or diarrhea.
- Loss of appetite and weight loss.
- Decreased sodium levels in your blood.
How effective is Xpovio?
About Xpovio – Selinexor This initial approval was based on data from a study that evaluated the effectiveness of the combination therapy in 83 patients with relapsed or refractory multiple myeloma. Overall 25.3% of patients responded to Xpovio and the median duration of response was 3.8 months.
What is the cost of Xpovio?
The cost for Xpovio oral tablet 20 mg is around $24,103 for a supply of 8, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans….Oral Tablet.
| Quantity | Per unit | Price |
|---|---|---|
| 4 (4 x 1 each) | $6,025.73 | $24,102.93 |
| 8 (4 x 2 each) | $3,012.87 | $24,102.93 |
What is the mechanism of action of selinexor?
Mechanism of action. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivating CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins.
Who is the company that makes selinexor?
Selinexor was developed by Karyopharm Therapeutics, a pharmaceutical company focused on the development of drugs that target nuclear transport. It was approved in the United States in July 2019, on the basis of a single-arm Phase IIb clinical trial.
What do you need to know about selinexor for cancer?
As a condition of approval, a confirmatory trial (s)must show that selinexor provides a clinical benefit in these patients.Selinexor is also being studied in the treatment of other types of cancer. Selinexor causes cell cycle arrest and apoptosis in cancer cells.
Who is eligible for the use of selinexor?
Selinexor is indicated for the treatment of relapsed or refractory multiple myeloma in combination with dexamethasone. Patients must have received at least 4 prior therapies and have disease which is refractory to least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody.
